Aurora kinase A (AURKA) belongs to the family of serine/threonine kinases, whose
activation is necessary for cell division processes via regulation of mitosis. AURKA shows …

The Myc proto-oncogene family consists of three members, C-MYC, MYCN, and MYCL,
which encodes the transcription factor c-Myc (hereafter Myc), N-Myc, and L-Myc …

Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome
(Ph) which results from a reciprocal translocation between chromosomes 9 and 22 [t (9; 22] …

Aurora kinases, a family of serine/threonine kinases, consisting of Aurora A (AURKA),
Aurora B (AURKB) and Aurora C (AURKC), are essential kinases for cell division via …

Chronic myeloid leukemia (CML) is driven by the BCR-ABL1 fusion protein, formed by a
translocation between chromosomes 9 and 22 that creates the Philadelphia chromosome …

Recent advances in high-throughput sequencing technologies and data science have
facilitated the development of precision medicine to treat cancer patients. Synthetic lethality …

Tyrosine kinase inhibitors have improved survival for patients with Philadelphia
chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL). However, prognosis for …

Hematological malignancies (HM) are a collection of malignant transformations originating
from cells in the primary or secondary lymphoid organs. Leukemia, lymphoma, and multiple …

Management of chronic myeloid leukemia (CML) in advanced phases remains a challenge
also in the era of tyrosine kinase inhibitors (TKIs) treatment. Cytogenetic clonal evolution …

Imatinib mesylate was the first tyrosine kinase inhibitor (TKI) approved for the management
of chronic myeloid leukemia. Imatinib produces acceptable responses in approximately 60 …